Quantification of Lymphokine Production in Human Disease

Ralph Snyderman(Duke University), Marilyn C. Pike(Bethesda Hospital), L. Meadows

Elsevier eBooks

January 1, 1979

10.1016/b978-0-12-178250-4.50012-x

Cited by 2

Related Papers

Pharmacological Treatment of Coronary Artery Disease With Recombinant Fibroblast Growth Factor-2

|Circulation|2002|652

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

|Annals of the Rheumatic Diseases|2013|340

Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure

|Kidney International|1999|305

Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase <scp>II</scp>, Randomized, <scp>Double‐Blind</scp>, <scp>Placebo‐Controlled</scp> Trial

|Arthritis & Rheumatology|2022|261

Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double‐Blind, Placebo‐Controlled Trials

|Arthritis & Rheumatology|2016|237